Literature DB >> 1992126

Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives.

S Ohkawa1, S Terao, Z Terashita, Y Shibouta, K Nishikawa.   

Abstract

A novel series of (3-pyridylmethyl)benzoquinone derivatives was molecular designed and synthesized for the dual purpose of inhibiting thromboxane A2 and leukotriene biosynthesis enzymes and scavenging active oxygen species (AOS). They were evaluated for inhibition of TXA2 synthase, inhibition of 5-lipoxygenase, and for their scavenging activity of AOS using the thiobarbituric acid method. 2,3,5-Trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone (24, CV-6504) was the most promising derivative since it showed efficient AOS scavenging activity (inhibition of lipid peroxidation in rat brain homogenates: IC50 = 1.8 x 10(-6) M) as well as potent, specific, and well-balanced inhibitory effects on both enzymes (inhibitory effect on TXA2 synthase in human blood, IC50 = 3.3 x 10(-7) M; inhibitory effect on 5-lipoxygenase in human blood, IC50 = 3.6 x 10(-7) M). In adriamycin-induced proteinuria in a rat model, compound 24 at 10 mg/kg per day (po) suppressed proteinuria by more than 50%. The proteinuria, however, could not be reduced by single administration of an inhibitor specific for thromboxane A2 synthase [(E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid (2, CV-4151)] or for 5-lipoxygenase [2-(12-hydroxy-5,10-dodecadiynyl)-3,5,6-trimethyl-1,4-benzoquinone (1, AA-861)]. The proteinuria was also not reduced by administration of an AOS scavenger, 2-O-octadecylascorbic acid (4, CV-3611). Triple function compounds such as compound 24 that specifically inhibit both enzymes as well as scavenge AOS possess a variety of pharmacologically beneficial effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1992126     DOI: 10.1021/jm00105a042

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Therapeutic Applications of Self-assembled Indole-3-butanoyl-polyethylenimine Nanostructures.

Authors:  Reena Singh; Diksha Jha; Uma Dhawan; Hemant K Gautam; Pradeep Kumar
Journal:  Indian J Microbiol       Date:  2022-04-18

2.  Selective inhibition of adenylate cyclase in bovine cortex by quinones: a novel cellular substrate for quinone cytotoxicity.

Authors:  O Moullet; J L Dreyer
Journal:  Biochem J       Date:  1994-05-15       Impact factor: 3.857

3.  Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1.

Authors:  Meihua Luo; Sarah Delaplane; Aihua Jiang; April Reed; Ying He; Melissa Fishel; Rodney L Nyland; Richard F Borch; Xiaoxi Qiao; Millie M Georgiadis; Mark R Kelley
Journal:  Antioxid Redox Signal       Date:  2008-11       Impact factor: 8.401

4.  Highly enantioselective borane reduction of heteroaryl and heterocyclic ketoxime ethers catalyzed by novel spiroborate ester derived from diphenylvalinol: application to the synthesis of nicotine analogues.

Authors:  Kun Huang; Francisco G Merced; Margarita Ortiz-Marciales; Héctor J Meléndez; Wildeliz Correa; Melvin De Jesús
Journal:  J Org Chem       Date:  2008-05-01       Impact factor: 4.354

5.  Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1 (Ape1/ref-1).

Authors:  Rodney L Nyland; Meihua Luo; Mark R Kelley; Richard F Borch
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

6.  A New and Efficient Approach to the Synthesis of Nicotine and Anabasine Analogues.

Authors:  Kun Huang; Margarita Ortiz-Marciales; Melvin De Jesús; Viatcheslav Stepanenko
Journal:  J Heterocycl Chem       Date:  2009-11-06       Impact factor: 2.193

7.  Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer.

Authors:  Gareth Watkins; Anthony Douglas-Jones; Robert E Mansel; Wen G Jiang
Journal:  Int Semin Surg Oncol       Date:  2005-10-26

8.  Mechanism of the anti-tumour effect of 2,3,5-trimethyl-6-(3-pyridylmethyl) 1,4-benzoquinone (CV-6504).

Authors:  H J Hussey; M J Tisdale
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Metabolism and pharmacokinetics of the anti-tumour agent 2,3,5-trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone (CV-6504).

Authors:  H J Hussey; M J Tisdale
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

10.  Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC).

Authors:  H J Hussey; M C Bibby; M J Tisdale
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.